Through the above experiments, among the four nanoparticles, TPNPs1 not only has the highest fluorescence intensity, but also has the highest binding efficiency with DOX, which meets the requirements of the experiment to the greatest extent. So, the TPNPs1 was selected to further explore its biomedical applications. To determine whether TPNPs1 and DOX are indeed mutually conjugated, the fluorescence spectra were applied in the process. Compared with Free DOX, the fluorescence intensity of TPNPs1 + DOX at the same dox concentration decreased significantly due to the fluorescence quenching at 595nm (
Fig. 3b), which also proves the interaction between TPNPs1 and DOX. In this process, we found an interesting phenomenon: the light emission area of TPNPs1 overlaps with the excitation light area of DOX, which means there is a fluorescence resonance phenomenon between them. Therefore, it is proposed that the TPNPs1 could be used to monitor the release of DOX in real time from TPNPs1 + DOX. The AFM images of TPNPs1 + DOX (
Fig. 3f) showed larger nanoparticles than TPNPs1 (
Fig. 3e), which demonstrated the conjugation between TPNPs1 and DOX. To study the feasibility of TPNPs1 for drug delivery and release, we set equal amounts of free DOX and TPNPs1 + DOX into dialysis tubes respectively, and then put them into PBS solution for sustained release experiment. At regular intervals, a 1 mL PBS solution was taken to detect the fluorescence intensity of DOX, to determine the released amount of DOX in PBS. The release rate was calculated according to the absorption intensity and a trend graph was drawn (
Fig. 3c). It can be seen that free DOX is released at 12h, while TPNPs1 released 60% of DOX and still released slowly after 24h. The results indicated that TPNPs1 can release most of the DOX into the environment and can be used for long-term treatment of lesions. The longer sustained release time allows the drug to maintain a high concentration for a long time, preventing the problem of the short half-life of the drug due to metabolism or other reasons. A longer half-life can reduce the frequency of drug use and improve the utilization rate of the drug during treatment. Afterward, to study the cytotoxicity of TPNPs1, a cytotoxicity test was conducted. The cell viability after incubating with Hela cells using TPNPs1 and TPNPs1 + DOX at four concentrations of 0, 1, 10, and 100 mg/mL, respectively. TPNPs1 still has very low cytotoxicity even at the highest concentrations, and TPNPs1 + DOX still retains its killing effect on cells even at lower concentrations (
Fig. 3d). These results demonstrated that TPNPs1 can indeed be used as a peptide nanoparticle that is not harmful to health, while the DOX carried can remain its killing effect on cancer cells.